CXCL10 and type 1 diabetes mellitus: Blockade of the CXCL10/CXCR3 axis with neutralizing antibody reduced T1D incidence in mice, and hopefully, a persistent remission of T1D could be achieved once anti-CD3 therapy is combined (17).